Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
| العنوان: | Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study |
|---|---|
| المؤلفون: | Hanae Miyagawa, Mitsuo Hashimoto, Jun Araya, Takanori Numata, Takeo Ishikawa, Hirofumi Utsumi, Shunsuke Minagawa, Kazuyoshi Kuwano, Hiromichi Hara, Saiko Nishioka, Keitaro Okuda |
| المصدر: | BMC Pulmonary Medicine BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-10 (2020) |
| بيانات النشر: | Springer Science and Business Media LLC, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, Eosinophilic asthma, Severity of Illness Index, Pulmonary function testing, Leukocyte Count, chemistry.chemical_compound, 0302 clinical medicine, Adrenal Cortex Hormones, Forced Expiratory Volume, Anti-Asthmatic Agents, 030212 general & internal medicine, Respiratory disease, Benralizumab, Middle Aged, Global evaluation of treatment effectiveness, medicine.anatomical_structure, Disease Progression, Corticosteroid, Drug Therapy, Combination, Female, Life study, Research Article, medicine.drug, Adult, Pulmonary and Respiratory Medicine, medicine.medical_specialty, medicine.drug_class, Antibodies, Monoclonal, Humanized, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, Aged, Retrospective Studies, lcsh:RC705-779, Eosinophilic chronic rhinosinusitis, business.industry, lcsh:Diseases of the respiratory system, Eosinophil, medicine.disease, Asthma, Eosinophils, Logistic Models, 030228 respiratory system, chemistry, Multivariate Analysis, Asthma, Aspirin-Induced, Interleukin-5, business, Mepolizumab |
| الوصف: | Background Benralizumab, an anti-interleukin-5 (IL-5) receptor α monoclonal antibody, significantly reduces the number of annual exacerbations and oral corticosteroid (OCS) maintenance doses for patients with severe eosinophilic asthma (SEA). However, few studies on the efficacy of this biologic in real life are available. The aim was to elucidate the efficacy of benralizumab by evaluating changes in clinical parameters after benralizumab treatment in patients with SEA. Methods From July 2018 to December 2019, 24 Japanese patients with SEA received benralizumab at Jikei University Hospital. We retrospectively evaluated the patients’ characteristics, parameters, numbers of exacerbations and maintenance OCS doses. Results Among the 24 patients, eleven patients had received mepolizumab treatment and were directly switched to benralizumab. The peripheral blood eosinophil and basophil counts significantly decreased after benralizumab treatment regardless of previous mepolizumab treatment. Pulmonary function, Asthma Control Test scores, the numbers of annual exacerbations and maintenance OCS doses in patients without previous mepolizumab treatment tended to improve without significant differences. Fourteen patients (58%) were responders according to the Global Evaluation of Treatment Effectiveness (GETE) score. The proportion of GETE responders among patients with aspirin-exacerbated respiratory disease (AERD) tended to be lower than that among patients without AERD (p = 0.085). After benralizumab treatment, the change in the forced expiratory volume in 1 s from baseline was 200 ml or greater in eight patients (33%), including three patients who were switched from mepolizumab. Conclusion Benralizumab treatment improved and controlled asthma symptoms based on the GETE score. |
| تدمد: | 1471-2466 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9efeec0cb87b1ebdad261febd939241Test https://doi.org/10.1186/s12890-020-01248-xTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c9efeec0cb87b1ebdad261febd939241 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14712466 |
|---|